Thomas Struengmann & family

Early Life

Thomas Strüngmann was born on February 16, 1950, in Mülheim an der Ruhr, Germany. Details about his early life are not widely available.

Rise to Success

Thomas and his twin brother Andreas co-founded Hexal AG in 1986. Under their leadership, Hexal became a leading generic drug manufacturer in Germany. In 2005, they sold Hexal and their stake in Eon Labs to Novartis for approximately $7 billion. Following the sale of Hexal, the Strüngmann brothers established investment firms, including Santo Holding and Athos Service, focusing on healthcare and biotech sectors. A pivotal moment came with their early investment in BioNTech SE, which developed the Pfizer-BioNTech COVID-19 vaccine, significantly increasing their wealth. The brothers earned $8 billion on their stake in BioNTech SE.

Key Business Strategies

The Strüngmann brothers have a long-term investment strategy. They focus on innovation in the healthcare sector, especially in biotechnology and pharmaceuticals. Their success has been driven by strategic investments in promising companies. They focus on identifying and investing in companies that have the potential for substantial growth.

Philanthropy

Thomas Strüngmann is known for his philanthropic activities. He, along with his brother, founded the Ernst Strüngmann Institute in Frankfurt, a neuroscience research center. They are also known to donate millions of dollars to various charities.